Email
Print
Tropical Spastic Paraparesis Market - Forecast(2024 - 2030)
The Tropical Spastic Paraparesis Market size is estimated to reach $765.7 million by 2027, growing at a CAGR of 9.8% during the forecast period 2022-2027.
Tropical spastic paraparesis (TSP) is an endemic neurological ailment discovered
in numerous tropical and subtropical areas, like the Caribbean Islands,
southern U.S., South America and Africa. The cause of TSP was ambiguous until the
mid-1980s when a significant linkage was identified between the human
retrovirus - human T-cell lymphotropic virus type 1 (also termed as HTLV-1) and TSP. TSP is presently termed HTLV-1 associated myelopathy/ tropical spastic
paraparesis or HAM/TSP. The HTLV-1 retrovirus is thought to bring about at
least 80 percent of the cases of HAM/TSP by harming the immune system. Spastic paraparesis is
a condition that is an exhibition of central nervous system ailments that
bring about injury to the motor cortex or descending motor pathways. Tropical
spastic paraparesis (TSP), is a medical condition that brings about weakness,
muscle spasms and sensory disturbance by the human T-lymphotropic virus leading to
paraparesis, and weakness of the legs. Treatment of TSP includes corticosteroids
to assist with inflammation. Although any success with corticosteroids is
short-lived, with symptoms worsening as the dosage is decreased. Certain signs
of Tropical Spastic Paraparesis include leg instability, urinary dysfunction, bowel
dysfunction, back pain, erectile issues and psoriasis. Patients with TSP may
also display uveitis (inflammation of the uveal tract of the eye), arthritis
(inflammation of one or more joints), pulmonary lymphocytic alveolitis
(inflammation of the lung tissues), polymyositis (an inflammatory muscle
disease), keratoconjunctivitis sicca (persistent dryness of the cornea and
conjunctiva) and infectious dermatitis (inflammation of the skin). Treatment of
TSP involves interferon alpha and corticosteroids.
The increasing transmission of HTLV-1 virus person-to-person through
infected cells and the surging treatment options for Tropical Spastic
Paraparesis including corticosteroids and interferon alpha are set to drive the
Tropical Spastic Paraparesis Market. The rising count of HTLV-1 seropositive
carriers becoming HAM/TSP patients is set to propel the growth of the Tropical
Spastic Paraparesis Industry during the forecast period 2022-2027. This
represents the Tropical Spastic Paraparesis Industry Outlook.
Tropical Spastic Paraparesis Market Report Coverage
The “Tropical Spastic Paraparesis
Market Report - Forecast (2022-2027)” by Industry ARC, covers an
in-depth analysis of the following segments in the Tropical Spastic Paraparesis Market.
Key Takeaways
- Geographically, South America (Tropical Spastic Paraparesis market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of Tropical Spastic Paraparesis requiring treatment options like corticosteroids in the South American region.
- Tropical Spastic Paraparesis Market growth is being driven by the increasing count of cases of Tropical Spastic Paraparesis (TSP) presently termed HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP requiring the application of corticosteroids to assist with inflammation. However, the reduced and limited geographical predominance of the ailment resulting in a tiny market for Tropical Spastic Paraparesis is one of the major factors hampering the growth of the Tropical Spastic Paraparesis Market.
- Tropical Spastic Paraparesis Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Tropical Spastic Paraparesis Market report.
Tropical Spastic Paraparesis Market: Market Share (%) by Region, 2021
For More Details On this report - Request For Sample
Tropical Spastic Paraparesis Market Segment Analysis - by Diagnostic Technique
The Tropical Spastic Paraparesis Market based on diagnostic techniques can be further segmented into MRI (Magnetic Resonance Imaging), and Lumbar Puncture. The MRI (Magnetic Resonance Imaging) Segment held the largest Tropical Spastic Paraparesis market share in 2021. This growth is owing to the surging application of Magnetic Resonance Imaging for the diagnosis of Tropical Spastic Paraparesis. Tropical Spastic Paraparesis has symptoms like polymyositis and keratoconjunctivitis sicca among other symptoms. The soaring Magnetic Resonance Imaging (MRI) brain investigations in patients with HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis are further propelling the growth of the MRI (Magnetic Resonance Imaging) segment.
Furthermore, the Lumbar Puncture segment is estimated to grow with the fastest CAGR of 10.5% during the forecast period 2022-2027 owing to the heightening application of lumbar puncture which may actively exhibit lymphocytes with corticosteroids being utilized for treatment.
Tropical Spastic Paraparesis Market Segment Analysis - by End-use Industry
The Tropical Spastic Paraparesis Market based on the end-use industry can be further segmented into Hospitals, Clinics, Diagnostic Centers and Others. The Hospitals Segment held the largest Tropical Spastic Paraparesis market share in 2021. This growth is owing to the increasing inclination of patients toward hospitals for diagnosis of Tropical Spastic Paraparesis. Tropical Spastic Paraparesis includes symptoms like polymyositis and keratoconjunctivitis sicca among other symptoms. The existence of progressive infrastructure and the effortless accessibility of qualified and skilled physicians in hospitals is further propelling the growth of this segment.
Furthermore, the Clinics segment is estimated to grow with the fastest CAGR of 10.9% during the forecast period 2022-2027 owing to the surging application of diagnostic techniques like magnetic resonance imaging and lumbar puncture for diagnosing Tropical Spastic Paraparesis in clinics together with corticosteroids and interferon alpha being used in treatment.
Tropical Spastic Paraparesis Market Segment Analysis - by Geography
The Tropical Spastic Paraparesis Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. South America (Tropical Spastic Paraparesis Market) held the largest Tropical Spastic Paraparesis market share with 40% of the overall market in 2021. The growth of this region is owing to the increasing pervasiveness of Tropical Spastic Paraparesis in the South American region. Tropical Spastic Paraparesis involves symptoms like polymyositis and keratoconjunctivitis sicca among other symptoms. The surging application of corticosteroids and interferon alpha for the treatment of Tropical Spastic Paraparesis and the rising count of cases in areas like the South Pacific Coast of Colombia are further propelling the growth of the Tropical Spastic Paraparesis Industry, thereby contributing to the Tropical Spastic Paraparesis Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the rising predominance of Tropical Spastic Paraparesis in Southern Japan in the Asia-Pacific region. The surging application of corticosteroids and interferon alpha for the treatment of Tropical Spastic Paraparesis together with the heightening patient pool in the tropical regions in Asia is further fuelling the progress of the Tropical Spastic Paraparesis Market in the Asia-Pacific region.
Tropical Spastic Paraparesis Market Drivers
Surging Applications of Corticosteroids and Interferon Alpha are Projected to Drive the Growth of Tropical Spastic Paraparesis Industry:
There is no well-established treatment program for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). HAM/TSP progresses in nearly 1 or 2% of individuals who bear HTLV-I. The outbreak of HAM/TSP happens subsequent to 5 or more years of accommodating the HTLV-I virus. Therefore, the ailment is rare in children. Corticosteroids may alleviate certain symptoms, however, are not possibly going to alter the course of the ailment. Clinical investigations recommend that interferon alpha offers advantages over brief periods and certain facets of ailment activity may be enhanced positively by utilizing interferon beta. Inflexible and spastic muscles may be attended to with Lioresal or tizanidine. Urinary dysfunction may be attended to with oxybutynin. The surging applications of Corticosteroids and Interferon Alpha are therefore fuelling the growth of the Tropical Spastic Paraparesis Industry, thereby contributing to the Tropical Spastic Paraparesis Industry Outlook, during the forecast period 2022-2027.
Soaring Research on Tropical Spastic Paraparesis is Expected to Boost the Growth of the Tropical Spastic Paraparesis Market:
Tropical spastic paraparesis has been identified clinically for numerous years in tropical areas and Japan. It is characterized by a chronic course in which mild-to-serious leg weakness establishes with raised muscle tone and extensor plantar responses. “One-half of patients have posterior column sensory signs and 15% have optic nerve involvement”. Individuals with Tropical Spastic Paraparesis may display polymyositis (an inflammatory muscle disease), keratoconjunctivitis sicca (persistent dryness of the cornea and conjunctiva) and infectious dermatitis (inflammation of the skin) among other signs and symptoms. The National Institute of Neurological Disorders and Stroke (NINDS) and additional institutes of the National Institutes of Health (NIH) direct research connected to HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in laboratories at the National Institutes of Health (NIH) and back added research by way of grants to principal medical institutions across the nation. Much of this research aims attention at discovering superior ways to avert, treat and eventually cure ailments like HAM/TSP. The soaring research on Tropical Spastic Paraparesis is therefore driving the growth of the Tropical Spastic Paraparesis Market during the forecast period 2022-2027.
Tropical Spastic Paraparesis Market Challenges
Challenges of Tropical Spastic Paraparesis are Hampering the Growth of the Tropical Spastic Paraparesis Market:
The lifetime risk of developing HAM/TSP is distinct among ethnic groups, ranging between 0.25 and 4%. In Tropical spastic paraparesis, HTLV-1 demonstrates raised cellular acquired immune response and soaring production of proinflammatory cytokines. IFN overexpression has been established as well. Also, the number of NK cells (CD56+ and CD16+) is decreased. Government initiative for raising awareness of the Tropical Spastic Paraparesis ailment and its accessible treatment may control the spread of infections. The dearth of adequate information on geographical predominance and epidemiology has limited the research activities. These issues are thus hampering the growth of the Tropical Spastic Paraparesis Market.
Tropical Spastic Paraparesis Industry Outlook
Development of different immunoassay kits for diagnosis of HTLV-1 virus, mergers and acquisitions, strategic agreements and diversifications are key strategies adopted by players in the Tropical Spastic Paraparesis Market. The top 10 companies in the Tropical Spastic Paraparesis market are:
- MP Biomedicals
- Fujirebio Inc.
- Quest Diagnostics
- DiaSorin S.p.A.
- Merck & Co. Inc.
- Ortho Clinical Diagnostics
- Trinity Biotech
- Meridian Bioscience
- bioMérieux SA
- Epicenter Technologies
Recent Developments
- In June 2022, H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio Holdings, Inc. and ADx NeuroSciences NV declared the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is anticipated to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.
- In December 2021, Quest Diagnostics carried out its acquisition of substantially all assets of Labtech Diagnostics, an independent clinical diagnostic laboratory provider serving physicians and patients principally in South and North Carolina, Georgia and Florida. Quest Diagnostics is a chief provider of diagnostic information services. The Dechert team that counseled Quest Diagnostics involved corporate partner Michael Darby and associate Verónica Casellas.
- In November 2020, Centogene N.V. and Fujirebio Europe declared to have entered a partnership to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing with further deployment in German airports. A portion of the agreement, Fujirebio will offer a steady supply of Lumipulse G SARS-CoV-2 Ag assays running on completely automated CLEIA-based LUMIPULSE G1200 instruments. Sample collection is to be carried out by CENTOGENE via the usual oropharyngeal swabs, with the analysis of the samples carried out at CENTOGENE test laboratories and the LUMIPULSE G1200 then backed by conveying high-quality outcomes in up to only 40 minutes from sample receipt in the laboratory. This concludes the Tropical Spastic Paraparesis Industry Outlook.
Relevant Reports:
Report Code: HCR 42929
Report Code: FBR 23655
Report Code: HCR 0320